A prospective randomised trial of different doses of intravitreal triamcinolone for diabetic macular oedema

Abstract

Higher doses of ivTA may prolong the duration of visual benefit in diabetic CSMO and seemed to result in more sustained reduction in macular oedema. Further studies are warranted to investigate the optimum dose of ivTA in treating diabetic CSMO.